Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: Detection in ascitic fluid and localization to primary sites and metastatic implants

Cancer

Volumn 82, Issue 1, 1998, Pages 152-158

  Menzin, Andrew W ^a,b   De Mola, J Ricardo Loret ^a,c   Bilker, Warren B ^a   Wheeler, James E ^a   Rubin, Stephen C ^a   Feinberg, Ronald F ^a,d  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ascites; Immunohistochemistry; Monoclonal antibodies; Oncofetal fibronectin; Ovarian cancer

Indexed keywords

FIBRONECTIN; MONOCLONAL ANTIBODY; ONCOFETAL ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES FLUID; CANCER LOCALIZATION; CELL ADHESION; CONTROLLED STUDY; ENDOMETRIOSIS; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; PRIORITY JOURNAL; TROPHOBLAST;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ASCITIC FLUID; CARCINOMA; CARCINOMA, ENDOMETRIOID; CELL ADHESION; COLORING AGENTS; ENDOMETRIOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; FEMALE; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL DISEASES; INTESTINE, SMALL; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEUM; TROPHOBLASTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031894473     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980101)82:1<152::AID-CNCR19>3.0.CO;2-1     Document Type: Article

References (34)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, 1996. CA A Cancer J Clin 1996; 46:5-27.
2. Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol 1993; 4:219-29.
3. Dean DC, Birkenmeier TM, Rosen GD, Weintraub SJ. Glycoprotein synthesis and secretion: expression of fibronectin and its cell surface receptors. Am Rev Respir Dis 1991; 144(Suppl):25-8.
4. Humphries MJ. Fibronectin and cancer: rationales for the use of antiadhesives in cancer treatment. Semin Cancer Biol 1993; 4:293-9.
5. Matsuura H, Hakomori S. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc Natl Acad Sci USA 1985; 82:6517-21.
6. Matsuura H, Takio K, Titani K, Greene T, Levery SB, Salyan ME, et al. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6: unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J Biol Chem 1988; 263:3314-22.
7. Matsuura H, Greene T, Hakomori S. An alpha-N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. J Biol Chem 1989; 264:10472-6.
8. Inufusa H, Nakamura M, Adachi T, Nakatani Y, Shindo K, Yasutomi M, et al. Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis. Cancer 1995; 75:2802-8.
9. Loridon-Rosa B, Vielh P, Matsuura H, Clausen H, Cuadrado C, Burtin P. Distribution of oncofetal fibronectin in human mammary tumors: immunoflorescence study on histological sections. Cancer Res 1990; 50:1608-12.
10. Mandel U, Therkildsen MH, Reibel J, Sweeney B, Matsuura H, Hakomori S, et al. Cancer-associated changes in glycosylation of fibronectin. Immunological localization of oncofetal fibronectin defined by monoclonal antibodies. APMIS 1992; 100:817-26.
11. Varani J, Schuger L, Fligiel SEG, Inman DR, Chakrabarty S. Production of fibronectin by human tumor cells and interaction with exogenous fibronectin: comparison of cell lines obtained from colon adenocarcinomas and squamous carcinomas of the upper aerodigestive tract. Int J Cancer 1991;47:421-5.
12. Nicolo G, Salvi S, Oliveri G, Borsi L, Castellani P, Zardi L. Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer. Cell Different Develop 1990; 32:401-8.
13. Feinberg RF, Kliman HJ, Lockwood CJ. Is oncofetal fibronectin a trophoblast glue for human implantation? Am J Pathol 1991; 138:537-43.
14. Feinberg RF, Kliman HJ, Bedian V, Monzon-Bordonaba F, Menzin AW, Wang C-L. Monoclonal antibody X18A4 identifies an oncofetal fibronectin epitope distinct from the FDC-6 binding site. Am J Obstet Gynecol 1995; 172:1526-36.
15. Feinberg RF, Wang C-L. Monoclonal antibody FDC-6 exhibits binding to human plasma fibronectin: a caveat for cervicovaginal oncofetal fibronectin testing? Am J Obstet Gynecol 1994; 171:1302-8.
16. Metz CE, Herman B, Wang P-L, Shen J-H, Kronman HB. Labroc1 Program. Chicago: The University of Chicago, Department of Radiology, 1993.
17. Swets JA, Pickett RM. Evaluation of diagnostic systems: methods from signal detection theory. New York: Academic Press, 1982.
18. Metz CE, Wang P-L, Kronman HB. A new approach for testing the significance of differences between ROC curves measured from correlated data. In: Deconinck F, editor. Information processing in medical imaging. The Hague: Martinus Nijhoff, 1984:432-5.
19. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993; 68:4-17.
20. Ruoslahti E, Giancotti FG. Integrins and tumor cell dissemination. Cancer Cells 1989; 1:119-26.
21. Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J. Expression and function of β1 and αvβ3 integrins in ovarian cancer. Gynecol Oncol 1995; 58:216-25.
22. Castellani P, Siri A, Rosellini C, Infusini E, Borsi L, Zardi L. Transformed human cells release different fibronectin variants than do normal cells. J Cell Biol 1986; 103:1671-7.
23. Akiyama SK, Larjava H, Yamada KM. Differences in the biosynthesis and localization of the fibronectin receptor in normal and transformed cultured human cells. Cancer Res 1990; 50:1601-7.
24. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, et al. Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res 1990; 50:6757-64.
25. Danen EHJ, Ten Berge PMJ, Van Muijen GNP, Van't Hofgrootenboer AE, Brocker EB, Ruiter DJ. Emergence of α5β1 fibronectin-and αvβ3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 1994; 24:249-56.
26. Seftor REB, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E, et al. Role of the αvβ3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992;89:1557-61.
27. Etoh T, Byers HR, Mihm MC Jr. Integrin expression in malignant melanoma and their role in cell attachment and migration on extracellular matrix proteins. J Dermatol 1992; 19:841-6.
28. Gerbes AL, Jungst D, Xie Y, Permanetter W, Paumgartner G. Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites: proposal of a diagnostic sequence. Cancer 1991; 68:1808-14.
29. Gerbes AL, Xie Y, Mezger J, Jungst D. Ascitic fluid concentrations of fibronectin and cholesterol: comparison of differential diagnostic value with the conventional protein determination. Liver 1990; 10:152-7.
30. Schölmerich J, Volk BA, Kottgen E, Ehlers S, Gerok W. Fibronectin concentration in ascites differentiates between malignant and nonmalignant ascites. Gastroenterology 1984; 87:1160-4.
31. Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC Jr. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer 1992; 70:2137-42.
32. Wilhelm O, Hafter R, Coppenrath E, Pflanz MA, Schmitt M, Babic R, et al. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to tumor stroma. Cancer Res 1988; 48:3507-14.
33. Menzin AW, de Mola JRL, Wang C-L, Feinberg RF. Oncofetal fibronectin and ovarian cancer [abstract]. J Soc Gynecol Invest 1995; 2:231.
34. Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, et al. A tumor-associated fibronectin isoform generated by the alternate splicing of messenger RNA precursors. J Cell Biol 1989; 108:1139-48.